2 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 2, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
Follow Allogene Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Recruiting | Allogene Therapeutics | 66 | 2025-11-13 | 2026-09-10 |
| Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product Hematologic Malignancies, Solid Tumors | Enrolling by invitation | Allogene Therapeutics | 50 | 2025-01-31 | 2026-10-23 | |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide - Large B-cell Lymphoma | Phase 2 | Recruiting | Allogene Therapeutics | 250 | 2024-06-18 | 2026-10-02 |
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy ALLO-647, Fludarabine, Cyclophosphamide - Relapsed/Refractory Large B Cell Lymphoma | Phase 2 | Terminated | Allogene Therapeutics | 2 | 2023-11-01 | 2026-03-02 |
| Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma ALLO-605, ALLO-647, Fludarabine - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Allogene Therapeutics | 6 | 2021-06-06 | 2024-06-28 |
| Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma ALLO-316, ALLO-647, Fludarabine - Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Active not recruiting | Allogene Therapeutics | 120 | 2021-02-24 | 2026-08-27 |
| Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) ALLO-501A, ALLO-647, Fludarabine - Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Allogene Therapeutics | 160 | 2020-05-21 | 2026-03-04 |
| Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) ALLO-715, ALLO-647, Fludarabine - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | Allogene Therapeutics | 73 | 2019-09-23 | 2026-05-13 |
| Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma ALLO-501, ALLO-647, Fludarabine - Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma | Phase 1 | Completed | Allogene Therapeutics | 50 | 2019-05-01 | 2026-03-02 |
Lymphoma (3) · Recurrence (3) · Multiple Myeloma (2) · Autoimmune Diseases (1) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Dermatomyositis (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myositis (1)
Cyclophosphamide (8) · fludarabine (8) · fludarabine phosphate (1) · nirogacestat (1)
United States (9) · Canada (3) · Australia (2) · Belgium (1) · South Korea (1)
PMID 39946666, PMID 37093350, PMID 38314087, PMID 39584380, PMID 42447427